MK-677 Research Evidence
The MK-677 evidence base: trials, journals, and what the data does not yet show.
Key Findings at a Glance
• MK-677 is one of the few growth hormone secretagogues with genuine randomized, placebo-controlled human trial data — including a 2-year study in healthy older adults, not just short pharmacokinetic studies. • A single oral dose produces a sustained rise in growth hormone and IGF-1 lasting roughly 24 hours, unlike the single discrete pulse produced by short-acting injectable GHRPs. • The best-known long-term trial (Nass et al., 2008) found MK-677 increased fat-free mass in older adults but did not improve physical function or strength outcomes over 2 years — a distinction often lost in casual discussion of the compound. • Appetite stimulation and mild fluid retention are the most consistently reported effects across trials, tracing directly back to MK-677's ghrelin-mimetic mechanism.
Reversal of Diet-Induced Catabolism
Murphy et al. (1998) demonstrated in a randomized, placebo-controlled trial that oral MK-677 reversed the negative nitrogen balance induced by a hypocaloric diet in healthy adults, with treated subjects maintaining nitrogen balance while placebo subjects did not. This was among the first human demonstrations that an orally active ghrelin mimetic could produce growth hormone and IGF-1 elevations sufficient to counteract a catabolic state — the finding that anchored later interest in sarcopenia and cachexia research. [Murphy MG, et al., 1998]
2-Year Trial in Healthy Older Adults
The most substantial human dataset comes from Nass et al. (2008), a randomized, double-blind, placebo-controlled trial in adults over 60 given MK-677 daily for 2 years. Fat-free mass increased significantly versus placebo, and IGF-1 levels rose into the young-adult reference range and stayed there for the full study duration. However, the trial found no significant improvement in measures of physical function, muscle strength, or insulin sensitivity — treated subjects also had a higher, though not statistically dangerous, incidence of increased fasting glucose and mild insulin resistance. This is the key nuance in MK-677's research record: body-composition changes reliably occur, but they have not translated into functional performance gains in controlled trials. [Nass R, et al., 2008]
Sleep Architecture
Because natural growth hormone secretion peaks during slow-wave sleep, and MK-677 sustains GH elevation across the sleep window specifically, several smaller studies have examined its effect on sleep quality. Findings suggest modest increases in REM sleep duration and subjective sleep quality in some cohorts, though data is far less extensive than the body-composition literature and effect sizes are inconsistent across studies.
References
- MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. · Murphy MG, Plunkett LM, Gertz BJ, He W, Wittreich J, Polvino WM, Clemmons DR · 1998
- Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. · Nass R, Pezzoli SS, Oliveri MC, Patrie J, Harman SM, Carlson OD, Egan JM, Evans WS, Veldhuis JD, Thorner MO · 2008
- Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group. · Murphy MG, Bach MA, Plotkin D, Bolognese J, Ng J, Krupa D, Cerchio K, Gertz BJ · 1999
- Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. · Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J, Krupa D, Gertz BJ · 2001
- Ibutamoren | C27H36N4O5S | CID 9576836 - PubChem - NIH